Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
Ocul Immunol Inflamm
; 29(1): 203-211, 2021 Jan 02.
Article
in En
| MEDLINE
| ID: mdl-32815757
Purpose: Immune checkpoint inhibitors (ICPIs), novel immunotherapy agents employed in the treatment of metastatic melanoma and other solid tumors, are associated with immune-related adverse events, including ocular inflammation. We review the current literature on immune checkpoint inhibitor-associated uveitis (ICIPU).Methods: A comprehensive literature review utilizing MEDLINE/PubMed, Cochrane, and Web of Science databases was conducted. One hundred and twenty-six cases of ICPIU reported in the literature prior to January 31, 2020 were identified and reviewed.Results: ICPIs were associated with 126 cases of anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis from 67 reports in the literature. Patients typically developed intraocular inflammation a median of 9 weeks after initiation of ICPI and 83.6% of the patients developed uveitis within 6 months. The vast majority of patients recovered to within one line of baseline vision in response to topical, local, and/or systemic steroid treatment as well as the cessation of medication.Conclusions: Prompt recognition and steroid treatment of ICPIU are critical to the care of patients receiving ICPIs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immune Checkpoint Inhibitors
/
Immunotherapy
Type of study:
Risk_factors_studies
/
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Ocul Immunol Inflamm
Journal subject:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: